Tsis ntev los no, Merck & Co., Inc. (Merck) tshaj tawm tias nws cov tshuaj PD-1 inhibitor, pembrolizumab, tau txais kev pom zoo los ntawm National Medical Products Administration (NMPA) ntawm Tuam Tshoj rau kev siv ua ke nrog lenvatinib thiab transarterial chemoembolization (TACE) rau kev kho mob rau cov neeg mob uas tsis tuaj yeem phais tau, tsis yog metastatic hepatocellular carcinoma.
Kev pom zoo rau cov cim tshiab no yog raws li cov ntaub ntawv los ntawm Theem III LEAP-012 kev sim tshuaj. Hauv qhov kev tshawb fawb ntau lub chaw, randomized, ob chav dig muag, Theem III (LEAP-012), 480 tus neeg mob tau raug sau npe thiab raug xaiv los ntawm random kom tau txais lenvatinib ntxiv rau TACE ntxiv rau pembrolizumab (n = 237) lossis TACE ntxiv rau ob chav placebo (n = 243).
Cov txiaj ntsig qhia tau tias qhov nruab nrab ntawm kev ciaj sia tsis muaj kev nce qib (PFS) yog 14.6 lub hlis hauv pawg lenvatinib ntxiv rau TACE ntxiv rau pembrolizumab, piv rau 10.0 lub hlis hauv pawg placebo. Cov nqi ciaj sia tag nrho 24-lub hlis (OS) yog 75% thiab 69%, raws li.
Lenvatinibyog ib qho tshuaj kinase inhibitor siv los kho qee hom mob qog noj ntshav. Cov tshuaj kinase inhibitors yog cov tshuaj enzyme inhibitors uas thaiv kev ua haujlwm ntawm ib lossis ntau cov protein kinases.
Pembrolizumab yog ib qho tshuaj monoclonal IgG4 kappa antibody uas ua rau tib neeg tawm tsam lub cell PD-1 (programmed death receptor-1) ntawm cov lymphocytes. Lub PD-1 receptor muab ib qho tseem ceeb "immune checkpoint," uas pab tiv thaiv lub cev tiv thaiv kab mob kom tsis txhob tawm tsam nws tus kheej. Qee hom qog nqaij hlav muaj PD-L1 (programmed death receptor ligand-1) ntau heev. Lwm hom qog nqaij hlav siv kev tiv thaiv kab mob uas hloov tau qhov twg lawv siv lub cev ntuj ntawm PD-L1 induction (kev tiv thaiv kev puas tsuaj los ntawm kev tiv thaiv kab mob) thiab hloov nws mus rau kev teb tiv thaiv qog nqaij hlav. Thaum PD-L1 koom nrog PD-1, T-cell ua haujlwm raug txwv; pembrolizumab thaiv PD-1: PDL-1 complex formation uas ua rau T-cell tua tau zoo dua.
Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.
Xov Tooj: 4008803716
Email：myimmnet@163.com
Lub sijhawm tshaj tawm: Lub Rau Hli-19-2025